JP6363082B2 - 層状複水酸化物 - Google Patents

層状複水酸化物 Download PDF

Info

Publication number
JP6363082B2
JP6363082B2 JP2015535105A JP2015535105A JP6363082B2 JP 6363082 B2 JP6363082 B2 JP 6363082B2 JP 2015535105 A JP2015535105 A JP 2015535105A JP 2015535105 A JP2015535105 A JP 2015535105A JP 6363082 B2 JP6363082 B2 JP 6363082B2
Authority
JP
Japan
Prior art keywords
active
ldh
layered double
double hydroxide
intercalated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015535105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500667A5 (enExample
JP2016500667A (ja
Inventor
トンプソン,クレア
コーデロ,マルセロ レオナルド ブラボ
コーデロ,マルセロ レオナルド ブラボ
オヘア,ダーモット,マイケル
Original Assignee
オックスフォード ファーマサイエンス リミテッド
オックスフォード ファーマサイエンス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード ファーマサイエンス リミテッド, オックスフォード ファーマサイエンス リミテッド filed Critical オックスフォード ファーマサイエンス リミテッド
Publication of JP2016500667A publication Critical patent/JP2016500667A/ja
Publication of JP2016500667A5 publication Critical patent/JP2016500667A5/ja
Application granted granted Critical
Publication of JP6363082B2 publication Critical patent/JP6363082B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
JP2015535105A 2012-10-05 2013-10-01 層状複水酸化物 Expired - Fee Related JP6363082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1217911.5 2012-10-05
GBGB1217911.5A GB201217911D0 (en) 2012-10-05 2012-10-05 Layered double hydroxides
PCT/GB2013/052554 WO2014053822A1 (en) 2012-10-05 2013-10-01 Layered double hydroxides

Publications (3)

Publication Number Publication Date
JP2016500667A JP2016500667A (ja) 2016-01-14
JP2016500667A5 JP2016500667A5 (enExample) 2016-11-17
JP6363082B2 true JP6363082B2 (ja) 2018-07-25

Family

ID=47294361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535105A Expired - Fee Related JP6363082B2 (ja) 2012-10-05 2013-10-01 層状複水酸化物

Country Status (16)

Country Link
US (1) US9642919B2 (enExample)
EP (2) EP2929876B1 (enExample)
JP (1) JP6363082B2 (enExample)
KR (1) KR20150063559A (enExample)
CN (1) CN104853748A (enExample)
AU (2) AU2013326298B2 (enExample)
BR (1) BR112015007529A2 (enExample)
CA (1) CA2887059A1 (enExample)
EA (1) EA034124B1 (enExample)
GB (1) GB201217911D0 (enExample)
IL (1) IL237947B (enExample)
IN (1) IN2015DN02576A (enExample)
MX (1) MX2015004188A (enExample)
PH (1) PH12015500744B1 (enExample)
WO (1) WO2014053822A1 (enExample)
ZA (2) ZA201502510B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520762D0 (en) * 2015-11-24 2016-01-06 Isis Innovation Novel pharmaceutical compositions
JP6557597B2 (ja) * 2015-12-25 2019-08-07 共栄社化学株式会社 層状複水酸化物
JP6982080B2 (ja) 2016-09-15 2021-12-17 パリ シアンス エ レトルParis Sciences Et Lettres 層状複水酸化物の層間アニオンを交換するための方法
CN109432450B (zh) * 2018-11-23 2021-07-13 北京化工大学 一种超分子纳米化学动力药物及其在肿瘤治疗方面的应用
US12268709B2 (en) * 2019-04-19 2025-04-08 National Institute For Materials Science Nitrogenous gas sustained releasing agent and nitrogenous gas sustained releaser composed of the same as well as nitrogenous gas sustained releasing method, respiratory equipment, package, and sustained releasing apparatus using the sustained releaser
EP4228611A4 (en) * 2020-10-17 2024-11-06 Mingowood Pharmacal, LLC FORMULATION AND NON-COVALENT STABILIZATION OF OLIVETOLIC ACID DERIVATIVES
WO2025192959A1 (ko) * 2024-03-13 2025-09-18 연세대학교 산학협력단 층상형 금속 인화물 혼성체 촉매, 이의 제조방법 및 이를 구비하는 수전해 장치

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606619A (ja) * 1983-06-27 1985-01-14 Kyowa Chem Ind Co Ltd 鉄分欠乏症処置剤及びその製法
US5079203A (en) 1990-05-25 1992-01-07 Board Of Trustees Operating Michigan State University Polyoxometalate intercalated layered double hydroxides
JP3681480B2 (ja) * 1996-09-27 2005-08-10 エーザイ株式会社 薬物の不快な味を隠蔽する組成物
GB0030460D0 (en) * 2000-12-14 2001-01-24 Isis Innovation Drug delivery system
JP4018983B2 (ja) 2000-12-19 2007-12-05 バブコック アンド ウイルコックス ボルンド エイピーエス 有害な廃棄物からオキシアニオン形成元素、特にクロムの浸出を減少させる方法
JP2004091421A (ja) * 2002-09-03 2004-03-25 Tayca Corp アスコルビン酸を取り込んだ層状複水酸化物およびそれを含む化粧料組成物
US20040138511A1 (en) 2003-01-10 2004-07-15 James Butler Aromatic alkylation process with direct recycle
AU2003902178A0 (en) 2003-05-07 2003-05-22 Commonwealth Scientific And Industrial Research Organisation Stabilization of waste material
CN1297276C (zh) 2004-06-14 2007-01-31 北京化工大学 5-氨基水杨酸插层药物缓释剂及其制备方法
US20090108233A1 (en) * 2004-12-24 2009-04-30 The Univeristy Of Queensland Preparation of suspensions
US20060140994A1 (en) 2004-12-27 2006-06-29 Bagwell Alison S Application of an antimicrobial agent on an elastomeric article
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100462071C (zh) * 2006-09-22 2009-02-18 北京化工大学 一种磁性超分子插层结构缓释型布洛芬及其制备方法
CN101493404B (zh) 2008-01-21 2011-08-10 安徽帝元生物科技有限公司 一种化肥养分控失剂控失率的检测方法
CN101440281B (zh) * 2008-11-25 2011-11-23 北京化工大学 苯并咔唑插层水滑石复合发光材料及其制备方法
ZA201000350B (en) 2009-02-05 2010-12-29 Univ Pretoria A degradable polymeric material
CN101507819B (zh) 2009-03-27 2011-01-05 北京化工大学 一种大粒径药物插层水滑石及其制备方法
CN101597474B (zh) 2009-07-03 2012-10-17 北京化工大学 增甘磷插层结构选择性红外吸收材料及其制备方法与应用
US20110040006A1 (en) 2009-08-17 2011-02-17 Basf Se Compositions with Improved Dirt Pickup Resistance Comprising Layered Double Hydroxide Particles
CN102218043B (zh) 2011-06-14 2013-03-27 宁夏医科大学 Ldh超分子组装型阿司匹林缓释片及其制备方法

Also Published As

Publication number Publication date
EA034124B1 (ru) 2019-12-30
WO2014053822A1 (en) 2014-04-10
ZA201502510B (en) 2017-09-27
EP2929876A1 (en) 2015-10-14
EA201590673A1 (ru) 2015-08-31
EP2929876B1 (en) 2019-12-25
AU2017219016B2 (en) 2018-07-26
AU2013326298A1 (en) 2015-04-23
EP2903598A1 (en) 2015-08-12
EP2903598B1 (en) 2019-05-01
AU2017219016A1 (en) 2017-09-07
PH12015500744A1 (en) 2015-05-25
IL237947B (en) 2018-04-30
CN104853748A (zh) 2015-08-19
CA2887059A1 (en) 2014-04-10
US20150258212A1 (en) 2015-09-17
US9642919B2 (en) 2017-05-09
KR20150063559A (ko) 2015-06-09
BR112015007529A2 (pt) 2017-07-04
AU2013326298B2 (en) 2017-10-05
WO2014053822A4 (en) 2014-05-30
MX2015004188A (es) 2015-07-17
PH12015500744B1 (en) 2015-05-25
IN2015DN02576A (enExample) 2015-09-11
ZA201702869B (en) 2018-08-29
JP2016500667A (ja) 2016-01-14
GB201217911D0 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
AU2017219016B2 (en) Layered double hydroxides
EP1993514B1 (en) Granular material comprising water-insoluble inorganic phosphate binders
JP6333926B2 (ja) 混合金属化合物
Li et al. Synthesis and controlled release properties of prednisone intercalated Mg− Al layered double hydroxide composite
Oh et al. LDH nanocontainers as bio-reservoirs and drug delivery carriers
Perioli et al. Intercalation and release of antiinflammatory drug diclofenac into nanosized ZnAl hydrotalcite-like compound
San Román et al. Drug release from layered double hydroxides and from their polylactic acid (PLA) nanocomposites
KR101951857B1 (ko) 마그헤마이트 또는 마그헤마이트/마그네타이트에 기초한 나노미립자 인산염 흡착제, 이의 제법 및 용도
EP3210600B1 (en) Mixed metal compounds used as antacids
EP1758612B1 (en) Composition comprising intercalated functional-active organic compounds
EP2209479A1 (en) Mixed metal compounds for treatment of hyperphos phataemia
JP2016500667A5 (enExample)
US10272057B2 (en) Layered double hydroxides
KR20090098940A (ko) 제산제
Shahabadi et al. Biological application of Layered double hydroxides in drug delivery systems
CA3116635A1 (en) Methods of treatment with mixed metal compounds
Chakraborty et al. Layered double hydroxides based ceramic nanocapsules as reservoir and carrier of functional anions
Pandya et al. Exploring the influence of l-amino acid side chain variations on magnetite nanoparticles: a comprehensive investigation of formation dynamics and biological functionality
Fisher Pharmaceutical applications of layered double hydroxides
Sichani et al. A Novel Approach to Magnetic Core-Shell Nanostructures of MgAl Layered Double Hydroxide for Controlled Drug Release of Mefenamic Acid
Mondal Mg-Al Layered Double Hydroxide Nano-Carrier for Controlled Release of anti-inflammatory Drug
AU2013263790A1 (en) Granular Material Comprising Water-Insoluble Inorganic Phosphate Binders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180627

R150 Certificate of patent or registration of utility model

Ref document number: 6363082

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees